ACCME data show commercial support for CME flat in 2007

Share this article:
Total commercial support of accredited CME scarcely budged in 2007, rising 1% to $1.2 billion, while the share of commercial support going to publishing and education companies declined 4.2% to $594 million, according to the ACCME's annual report.

Medical publishers and med ed agencies weren't the only providers to see support slide, data from the Accreditation Council for Continuing Medical Education (ACCME) show. Commercial support to government and military providers fell a whopping 94%, while support to hospitals plunged 18% and that going to medical schools fell 5%. Those gaining in commercial support: specialist societies and other non-profits, as well as insurance and managed care companies.

Total income reported was nonetheless up 6.5% overall, while the number of physician participants rose 5.4% and the number of CME activities increased by 20.8%.

However, the drop in commercial support suggests that congressional inquiries into industry funding of CME and criticism within academic and medical circles may be having an impact. Tom Sullivan, president of med ed firm Rockpointe Corp., says the reality is probably worse than the data suggest.

“I'm wondering if people are over-reporting,” said Sullivan. “I think there's probably been a drop in support and it's showing up as static because people are being more diligent in how they report.” Some firms, he suggested, may be including advertising and exhibits income, which is not considered commercial support, just to be on the safe side at a time of intense scrutiny on CME funding.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?